AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Argenica Therapeutics Ltd

0.190

-0.005-2.56%

Volume:19.85K

Turnover:4K

Market Cap:24.41M

PE:-2.50

High:0.210

Open:0.195

Low:0.190

Close:0.195

52wk High:0.695

52wk Low:0.087

Shares:128.46M

Float Shares:91.53M

Volume Ratio:0.55

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.076

EPS(LYR):-0.056

ROE:-117.81%

ROA:-61.45%

PB:7.09

PE(LYR):-3.38

Loading ...

Overview Company News Filings

Argenica Therapeutics - no Dividend Has Been Declared

THOMSON REUTERS

Argenica Therapeutics Ltd - FY Revenues from Ordinary Activities A$5.7 Mln

THOMSON REUTERS

Argenica's Drug Candidate for Severe Strokes Represents 'Highly Commercially Attractive Opportunity,' Euroz Hartleys Says

MT Newswires Live

Argenica Therapeutics Ltd-Arg007 (Xaranetide) Completes All Three FDA Requested Assays

THOMSON REUTERS

BRIEF-Argenica Therapeutics Says IND Application Advanced With Successful Completion Of Assay

Argenica Therapeutics Ltd - Two of Three FDA-Requested Assays Complete; Glp Herg Cardiac Safety Assay in Progress

THOMSON REUTERS

Argenica Therapeutics Ltd-Ind Application Advanced With Successful Completion of Assay

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/AGN.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AGN.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AGN.AU\",,,,,undefined,":{"symbol":"AGN.AU","market":"AU","secType":"STK","nameCN":"Argenica Therapeutics Ltd","latestPrice":0.19,"timestamp":1787724720000,"preClose":0.195,"halted":0,"volume":19846,"delay":0,"changeRate":-0.025641025641025664,"nameEN":"Argenica Therapeutics Ltd","floatShares":91529130,"shares":128456712,"eps":-0.076,"marketStatus":"Closed","change":-0.005,"latestTime":"08-26 16:12:00 AEST","open":0.195,"high":0.21,"low":0.19,"amount":3921,"amplitude":0.102564,"askPrice":0.2,"askSize":690,"bidPrice":0.19,"bidSize":29969,"shortable":3,"etf":0,"ttmEps":-0.076,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787788800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.195,"openAndCloseTimeList":[[1787702400000,1787724000000]],"volumeRatio":0.549012,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"AGN.AU","preClose":0.195,"auctionPrice":0.19,"auctionVolume":8000,"auctionTime":1787724515887,"referencePrice":0.19,"referenceTime":1787726520244,"auction":3,"marketStatus":"盘后竞价","timestamp":1787724515887}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AGN.AU\",,,,,undefined,":{"symbol":"AGN.AU","floatShares":91529130,"roa":"-61.45%","roe":"-117.81%","lyrEps":-0.056226,"volumeRatio":0.549012,"shares":128456712,"dividePrice":0,"high":0.21,"amplitude":0.102564,"preClose":0.195,"low":0.19,"week52Low":0.087,"pbRate":"7.09","psRate":"24.25","week52High":0.695,"institutionHeld":0,"latestPrice":0.19,"committee":0.954989,"eps":-0.076,"divideRate":0,"volume":19846,"delay":0,"ttmEps":-0.076,"open":0.195,"prevYearClose":0.295,"prevWeekClose":0.195,"prevMonthClose":0.155,"prevQuarterClose":0.096,"fiveDayClose":0.21,"twentyDayClose":0.15,"sixtyDayClose":0.13},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGN.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGN.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGN.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662760714","title":"Argenica Therapeutics - no Dividend Has Been Declared","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760714","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662760714?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:31","pubTimestamp":1787725875,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44M0ZH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662719760","title":"Argenica Therapeutics Ltd - FY Revenues from Ordinary Activities A$5.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662719760","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662719760?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:31","pubTimestamp":1787725875,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44M0ZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642255266","title":"Argenica's Drug Candidate for Severe Strokes Represents 'Highly Commercially Attractive Opportunity,' Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2642255266","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642255266?lang=en_us&edition=fundamental","pubTime":"2026-06-12 10:00","pubTimestamp":1781229653,"startTime":"0","endTime":"0","summary":"Argenica Therapeutics'  ARG-007 drug candidate is supported by a compelling body of evidence in patients with severe strokes, which represents a \"highly commercially attractive opportunity,\" Euroz Hartleys said in a Friday note.It completed a cardiac safety assay for its ARG-007 drug candidate, the third and final safety study requested by the US Food and Drug Administration, addressing the last outstanding requirement of the clinical hold placed on its Investigational New Drug application to begin trials in the US. This is a key milestone, clearing the path to its proposed Phase 2b trial in ischaemic stroke.In parallel, the firm is advancing ARG-007 toward a Phase 1b trial in traumatic brain injury and is in the final stages of talks with hospital and academic partners. This gives the company a second shot in another large market, with non-dilutive funding adding to the appeal.The investment firm retained its speculative buy rating on Argenica as well as its AU$1.30 per share price ta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGN.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642711054","title":"Argenica Therapeutics Ltd-Arg007 (Xaranetide) Completes All Three FDA Requested Assays","url":"https://stock-news.laohu8.com/highlight/detail?id=2642711054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642711054?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:33","pubTimestamp":1781130789,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nTUE2H12KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637709338","title":"BRIEF-Argenica Therapeutics Says IND Application Advanced With Successful Completion Of Assay","url":"https://stock-news.laohu8.com/highlight/detail?id=2637709338","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637709338?lang=en_us&edition=fundamental","pubTime":"2026-05-21 09:37","pubTimestamp":1779327452,"startTime":"0","endTime":"0","summary":"BRIEF-Argenica Therapeutics Says IND Application Advanced With Successful Completion Of AssayMay 21  - Argenica Therapeutics Ltd AGN.AX:IND APPLICATION ADVANCED WITH SUCCESSFUL COMPLETION OF ASSAYCOMPLETES FDA-REQUESTED GLP MOUSE LYMPHOMA ASSAY WITH NO EVIDENCE OF GENOTOXICITYTWO OF THREE FDA-REQUESTED ASSAYS COMPLETE; GLP HERG CARDIAC SAFETY ASSAY IN PROGRESSFurther company coverage: AGN.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUE6ZW7BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","AGN.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637871835","title":"Argenica Therapeutics Ltd - Two of Three FDA-Requested Assays Complete; Glp Herg Cardiac Safety Assay in Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2637871835","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637871835?lang=en_us&edition=fundamental","pubTime":"2026-05-21 07:01","pubTimestamp":1779318103,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUE6ZW7BT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGN.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637718368","title":"Argenica Therapeutics Ltd-Ind Application Advanced With Successful Completion of Assay","url":"https://stock-news.laohu8.com/highlight/detail?id=2637718368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637718368?lang=en_us&edition=fundamental","pubTime":"2026-05-21 07:01","pubTimestamp":1779318103,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUE6ZW7BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}